SEC filing · 8-K

Larimar Therapeutics, Inc.: Executive or director change

Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026.

Filed September 29, 2026

Positive for the company

What happened

The Board of Directors appointed John B. Harlow, Jr. as President and Chief Operating Officer under an employment agreement effective September 29, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Larimar Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.